4/17
08:12 pm
jagx
Proof-of-Concept Data for Rare Disease Indications MVID and SBS-IF for Jaguar Health's Crofelemer to be Presented at April 2025 ELITE PED-GI Congress [Yahoo! Finance]
Neutral
Report
Proof-of-Concept Data for Rare Disease Indications MVID and SBS-IF for Jaguar Health's Crofelemer to be Presented at April 2025 ELITE PED-GI Congress [Yahoo! Finance]
4/1
04:42 pm
jagx
Jaguar Health Announces Closing of Bridge Financing Priced At-The-Market Under Nasdaq Rules [Yahoo! Finance]
Low
Report
Jaguar Health Announces Closing of Bridge Financing Priced At-The-Market Under Nasdaq Rules [Yahoo! Finance]
3/31
08:47 am
jagx
Jaguar Health Reports 2024 Financials: 2024 Net Revenue Up Approximately 20% Over 2023 [Yahoo! Finance]
Low
Report
Jaguar Health Reports 2024 Financials: 2024 Net Revenue Up Approximately 20% Over 2023 [Yahoo! Finance]
3/28
02:05 am
jagx
Jaguar Health, Inc. (NASDAQ: JAGX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
Jaguar Health, Inc. (NASDAQ: JAGX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
3/26
09:52 am
jagx
Jaguar Health CEO, Board Members, Other C-Suite Members, and Institutional and Accredited Investors Invest in $3.448 Million Bridge Financing Priced At-The-Market Under Nasdaq Rules [Yahoo! Finance]
Low
Report
Jaguar Health CEO, Board Members, Other C-Suite Members, and Institutional and Accredited Investors Invest in $3.448 Million Bridge Financing Priced At-The-Market Under Nasdaq Rules [Yahoo! Finance]
3/20
02:06 am
jagx
Jaguar Health, Inc. (NASDAQ: JAGX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Low
Report
Jaguar Health, Inc. (NASDAQ: JAGX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
2/18
09:22 am
jagx
Jaguar Health Extends Collaboration for Possible Tropical Disease Priority Review Voucher and Cholera Indication for NP-300 [Yahoo! Finance]
High
Report
Jaguar Health Extends Collaboration for Possible Tropical Disease Priority Review Voucher and Cholera Indication for NP-300 [Yahoo! Finance]
2/13
09:17 am
jagx
Jaguar Health Presenting February 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts [Yahoo! Finance]
Low
Report
Jaguar Health Presenting February 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts [Yahoo! Finance]
2/3
09:30 am
jagx
Jaguar Health Announces First Patient Dosed in Short Bowel Syndrome with Intestinal Failure in Investigator-Initiated Trial of Crofelemer; Proof-of-Concept Data Potentially Available H1 2025
Medium
Report
Jaguar Health Announces First Patient Dosed in Short Bowel Syndrome with Intestinal Failure in Investigator-Initiated Trial of Crofelemer; Proof-of-Concept Data Potentially Available H1 2025
1/29
08:30 am
jagx
Jaguar Health Supports Evaluation of FDA-Approved Crofelemer to Address GI Side Effects of GLP-1 and Other Weight Loss Therapies: Files Patent Application with USPTO
Medium
Report
Jaguar Health Supports Evaluation of FDA-Approved Crofelemer to Address GI Side Effects of GLP-1 and Other Weight Loss Therapies: Files Patent Application with USPTO
1/22
09:00 am
jagx
Jaguar Health Announces First Patient Dosed in Investigator-Initiated Trial (IIT) Evaluating Crofelemer for the Rare Disease Indication of Microvillus Inclusion Disease (MVID), with Proof-of-Concept (POC) Data Potentially Available H1 2025
Medium
Report
Jaguar Health Announces First Patient Dosed in Investigator-Initiated Trial (IIT) Evaluating Crofelemer for the Rare Disease Indication of Microvillus Inclusion Disease (MVID), with Proof-of-Concept (POC) Data Potentially Available H1 2025